MARKET OUTLOOK Rheumatoid arthritis (RA) patients refractory to one or more...
MARKET OUTLOOK Rheumatoid arthritis (RA) patients refractory to one or more TNF-&alp......
MARKET OUTLOOK Rheumatoid arthritis (RA) is disease characterized by...
MARKET OUTLOOK Rheumatoid arthritis (RA) is disease characterized by chronic and progressive joint inflammation that commonly leads to permanent, debilitating tissue da......
Coming Soon – August 2019 Eli Lilly’s Olumiant is the second-in-class...
Coming Soon – August 2019 Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (RA) in the United States. Its...
Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for...
Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (RA) in the...
The mature rheumatoid arthritis (RA) market boasts ten different biologics...
The mature rheumatoid arthritis (RA) market boasts ten different biologics representing several distinct drug classes, including blockbuster tumor necros......
MARKET OUTLOOK Eli Lilly’s Olumiant is the second-in-class Jak inhibitor...
MARKET OUTLOOK Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis...
Five TNF inhibitors, five biologics with alternative mechanisms of action,...
Five TNF inhibitors, five biologics with alternative mechanisms of action, and two JAK inhibitors are approved for the treatment of rheumatoid arthritis (RA) in the EU5 (France, Ge...
Rheumatoid arthritis (RA) treatment is typically initiated with cost-effective...
Rheumatoid arthritis (RA) treatment is typically initiated with cost-effective conventional DMARD...
Introduction: The crowded U.S. rheumatoid arthritis (RA) market boasts nine...
Introduction: The crowded U.S. rheumatoid arthritis (RA) market boasts nine different biologics representing five distinct drug classes, including the blockbuster tumor......
Rheumatoid arthritis (RA) treatment typically begins with one or more...
Rheumatoid arthritis (RA) treatment typically begins with one or more conventional DMARDs, follow......
MARKET OUTLOOK Treatment of rheumatoid arthritis (RA) is typically initiated...
MARKET OUTLOOK Treatment of rheumatoid arthritis (RA) is typically initiated with cost-effective conventional ...
Introduction: The moderate to severe rheumatoid arthritis (RA) market is...
Introduction: The moderate to severe rheumatoid arthritis (RA) market is crowded; multiple targeted therapies are available, including nine different branded biologics, a b......
Introduction: The lucrative EU5 rheumatoid arthritis market is dominated by...
Introduction: The lucrative EU5 rheumatoid arthritis market is dominated by biologics, including five tumor necrosis factor (...
Abstract: The mature rheumatoid arthritis (RA) market boasts ten different...
Abstract: The mature rheumatoid arthritis (RA) market boasts ten different biologics representing several distinct drug classes, including blockbuster tumor necrosis facto......
Rheumatoid arthritis (RA) treatment is typically initiated with cost-effective...
Rheumatoid arthritis (RA) treatment is typically initiated with cost-effective conventional DMARD......
Two of the largest pharmacy benefits managers (PBMs) in the United States,...
Two of the largest pharmacy benefits managers (PBMs) in the United States, Express Scripts and CVS Health, have set traditional U.S. drug reimbursem......
Two of the largest pharmacy benefits managers (PBMs) in the United States,...
Two of the largest pharmacy benefits managers (PBMs) in the United States, Express Scripts and CVS Health, have set traditional U.S. drug reimbursem......
Rheumatoid arthritis (RA) treatment is typically initiated with cost-effective...
Rheumatoid arthritis (RA) treatment is typically initiated with cost-effective conventional DMARDs, such as methotrexate. The U.S. market for conventional DMARD-refractory RA patients is crowded wi......
About DRG Epidemiology DRG’s Epidemiology provides bottom-up, patient-level...
About DRG Epidemiology DRG’s Epidemiology provides bottom-up, patient-level forecasts, detailing disease trends from 10- to 20-year outlook periods to help you validat...
About DRG Epidemiology DRG’s Epidemiology provides bottom-up, patient-level...
About DRG Epidemiology DRG’s Epidemiology provides bottom-up, patient-level forecasts, detailing disease trends from 10- to 20-year outlook periods to help you validat...
